STS

KBR Announces First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 1, 2023

HOUSTON, May 1, 2023 /PRNewswire/ -- KBR, Inc. (NYSE: KBR) today announced its first quarter 2023 financial results.

Key Points: 
  • HOUSTON, May 1, 2023 /PRNewswire/ -- KBR, Inc. (NYSE: KBR) today announced its first quarter 2023 financial results.
  • "KBR's incredible people have once again delivered outstanding results in Q1," said Stuart Bradie, KBR president and CEO.
  • "Strong underlying growth and margin expansion drove earnings performance and momentum continued with an excellent bookings quarter.
  • "Of particular note in the quarter is that our bookings were in strategic areas across our portfolio - energy security, national security, defense modernization, space and sustainability.

Avelo Airlines Continues Central Oregon Expansion with New Exclusive Nonstop Service to California Wine Country

Retrieved on: 
Wednesday, April 26, 2023

REDMOND, Ore. and BEND, Ore., April 26, 2023 /PRNewswire/ -- Avelo Airlines announced today it is expanding service at Central Oregon's Redmond Municipal Airport (RDM) with new nonstop service to Sonoma / Santa Rosa, California. Avelo will be the only airline offering nonstop flights between Central Oregon and California Wine Country's Charles M. Schulz-Sonoma County Airport (STS).

Key Points: 
  • REDMOND, Ore. and BEND, Ore., April 26, 2023 /PRNewswire/ -- Avelo Airlines announced today it is expanding service at Central Oregon's Redmond Municipal Airport (RDM) with new nonstop service to Sonoma / Santa Rosa, California.
  • Avelo will be the only airline offering nonstop flights between Central Oregon and California Wine Country's Charles M. Schulz-Sonoma County Airport (STS).
  • We are excited to announce more service from Central Oregon with this new nonstop route to Sonoma County.
  • Adding another new nonstop destination further demonstrates the draw of Central Oregon tourism as well as our vibrant business community.

EBA consults on the draft Guidelines on the STS criteria for on-balance-sheet securitisations

Retrieved on: 
Friday, April 21, 2023

21 April 2023

Key Points: 
  • 21 April 2023
    The European Banking Authority (EBA) launched today a public consultation on its draft Guidelines on the criteria related to simplicity, standardisation and transparency and additional specific criteria for on-balance-sheet securitisations (so-called STS criteria).
  • These Guidelines will ensure a harmonised interpretation of these STS criteria, in alignment with the EBA Guidelines for traditional securitisations.
  • With the introduction of STS criteria for on-balance-sheet securitisations in the Securitisation Regulation, on-balance-sheet securitisations are now eligible for preferential risk-weight treatment under the Capital Requirements Regulation (CRR).
  • The draft Guidelines also propose targeted amendments to the Guidelines for non-ABCP securitisation and ABCP securitisation.

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

Retrieved on: 
Monday, April 17, 2023

SYDNEY, AUSTRALIA, April 17, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of an open-label Phase II trial evaluating eftilagimod alpha (efti), a soluble LAG-3 protein and MHC Class II agonist, in combination with pembrolizumab and radiotherapy in up to 40 soft tissue sarcoma (STS) patients in the neoadjuvant (prior to surgery) setting.

Key Points: 
  • Immutep will provide efti at no cost as well as technical support.
  • The trial will be led by Co-Principal Investigators, Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skłodowska-Curie National Research Institute of Oncology.
  • Dr. Paweł Sobczuk, stated: “We are excited to begin this chemotherapy-free study combining radiotherapy with the novel immunotherapy, eftilagimod alpha, and pembrolizumab.
  • The dosing of the first patient is anticipated in the first half of calendar year 2023.

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

Retrieved on: 
Monday, April 17, 2023

-- Prespecified Pooled Immunogenicity Analyses of Data from Both Adult Phase 2 Studies Showed the VAX-24 2.2mcg Dose Met OPA Non-Inferiority Criteria for All 20 STs Common with PCV20 and Superiority Criteria for the Four Additional VAX-24 STs --

Key Points: 
  • In the Phase 2 study in adults aged 65 and older, VAX-24 demonstrated robust OPA immune responses for all 24 serotypes at all doses studied, confirming the prior adult study results.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • “We believe the positive results from the Phase 2 study in adults aged 65 and older confirm the clinical potential of VAX-24 in the adult population.
  • The Company also reported the full six-month safety results from the VAX-24 Phase 2 study in adults aged 65 and older and the VAX-24 Phase 1/2 study in adults aged 18-64.

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 13, 2023

Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.

Key Points: 
  • Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.
  • Additionally, uPARAP receptor levels may serve as a potential biomarker for patient enrichment in clinical studies of such uPARAP-targeting ADCs.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, said: "We are excited to share data on the expression of uPARAP in soft tissue and bone sarcoma.
  • In addition to its differentiated expression profile in multiple sarcoma subtypes uPARAP is a constitutively recycling endocytic receptor with unique internalization properties, making it a highly attractive ADC target."

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 13, 2023

Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.

Key Points: 
  • Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.
  • Additionally, uPARAP receptor levels may serve as a potential biomarker for patient enrichment in clinical studies of such uPARAP-targeting ADCs.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, said: "We are excited to share data on the expression of uPARAP in soft tissue and bone sarcoma.
  • In addition to its differentiated expression profile in multiple sarcoma subtypes uPARAP is a constitutively recycling endocytic receptor with unique internalization properties, making it a highly attractive ADC target."

JW Marriott Grand Rapids chooses Noventri to Provide State-of-the-Art Digital Signage Solutions

Retrieved on: 
Thursday, April 6, 2023

SMITHSBURG, Md., April 6, 2023 /PRNewswire-PRWeb/ -- JW Marriott Grand Rapids has chosen Noventri, a leading provider of innovative digital signage solutions, to provide state-of-the-art digital signage throughout its impressive property. This partnership allows the hotel to enhance its guest experience and streamline its communication efforts. The JW Marriott Grand Rapids is a luxurious, upscale hotel in the heart of the Hotel District in downtown Grand Rapids. Boasting 331 well-appointed guest rooms and suites, and over 15,000 square feet of flexible meeting space that includes one large ballroom and 14 uniquely configured meeting, breakout and banquet rooms.

Key Points: 
  • JW Marriott Grand Rapids has chosen Noventri, a leading provider of innovative digital signage solutions, to provide state-of-the-art digital signage throughout its impressive property.
  • SMITHSBURG, Md., April 6, 2023 /PRNewswire-PRWeb/ -- JW Marriott Grand Rapids has chosen Noventri, a leading provider of innovative digital signage solutions, to provide state-of-the-art digital signage throughout its impressive property.
  • The JW Marriott Grand Rapids is a luxurious, upscale hotel in the heart of the Hotel District in downtown Grand Rapids.
  • The JW Marriott Grand Rapids hotel is supported by Noventri's top-tier customer service that covers every aspect of its digital signage needs.

Intelitek Aligns Industry 4.0 Training Curriculum with NIMS Industry 4.0 Smart Credentials for Production Specialists

Retrieved on: 
Thursday, March 23, 2023

DERRY, N.H., March 23, 2023 /PRNewswire-PRWeb/ -- Demand is high for production line workers proficient in Industry 4.0 technology innovations. That demand will grow as more complex systems are integrated in manufacturing and industrial processes. To help schools prepare their students for current and future jobs, Intelitek has delivered new training solutions for Industry 4.0 that are aligned to the National Institute for Metalworking Skills' (NIMS) Smart Training Solutions (STS), an innovative framework for modernizing training to keep up with the pace of emerging technology and building a bridge between educators and employers.

Key Points: 
  • Aligning training with smart credentials truly prepares students for what they will face on the job and validates their expertise."
  • Intelitek's Industry 4.0 curriculum advances learners' expertise in the broader industrial ecosystem as well as new Industry 4.0 technology innovations.
  • The Intelitek Industry 4.0 training labs include standalone labs for Smart Sensors, Condition Based Monitoring, Predictive Maintenance and Cybersecurity.
  • Intelitek NIMS Approved Performance measures for Industry 4.0 Production Technician are available to Intelitek customers so they are able to complete the NIMS Smart Credentialing process after finishing their studies.

Samsung Announces Ultra-Wideband Chipset with Centimeter-Level Accuracy for Mobile and Automotive Devices

Retrieved on: 
Tuesday, March 21, 2023

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced its first ultra-wideband (UWB) chipset, the Exynos Connect U100.

Key Points: 
  • Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced its first ultra-wideband (UWB) chipset, the Exynos Connect U100.
  • With single-digit centimeter accuracy, the new UWB solution is optimized for use in mobile, automotive and Internet of Things (IoT) devices, offering precise distance and location information.
  • Leveraging time of arrival (ToA) and 3D angle of arrival (AoA) measurements, Samsung’s Exynos Connect U100 provides an accuracy of single-digit centimeters and under five degrees.
  • Through its power-saving mode, the U100 can maximize the battery life of mobile and automotive solutions as well as IoT devices like smart tracking tags that run on batteries with limited power capacity.